Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
Insider and Institutional Ownership
8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by insiders. Comparatively, 54.1% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Quoin Pharmaceuticals has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Quoin Pharmaceuticals | N/A | -210.50% | -99.41% |
| Nutriband | -398.29% | -85.40% | -73.45% |
Valuation & Earnings
This table compares Quoin Pharmaceuticals and Nutriband”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quoin Pharmaceuticals | N/A | N/A | -$8.96 million | ($31.73) | -0.66 |
| Nutriband | $2.58 million | 22.43 | -$10.48 million | ($2.87) | -1.67 |
Quoin Pharmaceuticals has higher earnings, but lower revenue than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and price targets for Quoin Pharmaceuticals and Nutriband, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quoin Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Nutriband | 1 | 1 | 1 | 0 | 2.00 |
Nutriband has a consensus target price of $13.00, suggesting a potential upside of 170.55%. Given Nutriband’s stronger consensus rating and higher probable upside, analysts plainly believe Nutriband is more favorable than Quoin Pharmaceuticals.
Summary
Nutriband beats Quoin Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
